Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NILEAD: Nilotinib BE in Early Alzheimer's Disease
NCT05143528Phase 3Not yet recruiting
- Sponsor
- KeifeRx
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of nilotinib in Alzheimer's disease (AD) (3 arms), sponsored by KeifeRx. Primary endpoint: Clinical Dementia Rating Scale - Sum of Boxes at 72 weeks. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
nilotinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05143528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143528.